FibroGen, Inc.
FGEN
$8.12
$0.040.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 117.54% | 200.42% | -80.57% | -36.71% | -130.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 117.54% | 200.42% | -80.57% | -36.71% | -130.54% |
| Cost of Revenue | -89.08% | -82.40% | -77.14% | -62.30% | -45.34% |
| Gross Profit | 95.55% | 86.44% | 76.62% | 67.12% | -49.61% |
| SG&A Expenses | -20.95% | -37.57% | -40.92% | -42.96% | -74.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -76.49% | -73.28% | -69.88% | -57.91% | -54.80% |
| Operating Income | 84.43% | 76.78% | 68.63% | 60.88% | 13.05% |
| Income Before Tax | 78.17% | 65.70% | 59.04% | 52.55% | 18.46% |
| Income Tax Expenses | 80.27% | 76.71% | 14.11% | -6.75% | -1,538.71% |
| Earnings from Continuing Operations | 78.17% | 65.69% | 59.09% | 52.60% | 18.62% |
| Earnings from Discontinued Operations | 239.68% | 79.04% | 587.71% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 277.07% | 98.77% | 95.84% | 83.26% | 58.60% |
| EBIT | 84.43% | 76.78% | 68.63% | 60.88% | 13.05% |
| EBITDA | 84.61% | 76.88% | 68.55% | 60.51% | 11.16% |
| EPS Basic | 273.95% | 98.77% | 95.86% | 83.58% | 59.90% |
| Normalized Basic EPS | 82.36% | 75.28% | 67.72% | 61.03% | 15.01% |
| EPS Diluted | 273.95% | 98.77% | 95.86% | 83.58% | 59.90% |
| Normalized Diluted EPS | 82.36% | 75.28% | 67.72% | 61.03% | 15.01% |
| Average Basic Shares Outstanding | 1.84% | 2.28% | 2.52% | 3.14% | 3.10% |
| Average Diluted Shares Outstanding | 1.84% | 2.28% | 2.52% | 3.14% | 3.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |